← Back to Search
Time Trend Of Mesothelioma Incidence In The United States And Projection Of Future Cases: An Update Based On SEER Data For 1973 Through 2005
B. Price, A. Ware
Published 2009 · Medicine
Download PDFAnalyze on Scholarcy
The time trend of mesothelioma incidence and projections of future cases provide useful information for analyzing proposed public health interventions where asbestos exposure may be an issue, evaluating regulatory proposals, and estimating the remaining potential costs of programs to compensate individuals with asbestos-related diseases. We used the April 2008 release of Surveillance, Epidemiology, and End Results (SEER) data, which covers 1973 through 2005, to analyze the time trends in age-adjusted mesothelioma incidence and to estimate an age and birth-cohort model to project the number of future mesothelioma cases. The increase in the number of SEER cancer registries from 13 to 17 in 2000 had little effect on the time pattern of age-adjusted mesothelioma incidence, and the pattern over time of pleural mesothelioma was indistinguishable from the pattern for total mesothelioma defined as sum of pleural and peritoneal cases. Our analysis suggests that the SEER registries viewed as a sample of the U.S. population over-represents high mesothelioma incidence, a fact that we accounted for in our projections. For 2008 we estimate approximately 2,400 cases, with asbestos the likely cause in 58%. We project that asbestos will no longer be a factor in mesothelioma cases after the year 2042. For 2008 through 2042, we estimate slightly more than 68,000 total cases, with asbestos the likely cause in 34%.
This paper references
Diffuse malignant epithelial mesotheliomas of the peritoneum in women
S. Kerrigan (2002)
Geographic distribution of incident mesothelioma in Connecticut men, 1990–99
A. Polednak (2003)
The epidemiology of mesothelioma in historical context.
J. C. Mcdonald (1996)
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005
S. Moolgavkar (2009)
Surveillance, Epidemiology, and End Results Program (www
Asbestos and its diseases
J. Craighead (2008)
293. Overview of Exposure Data in the NIOSH 2002 Work-Related Lung Disease (WoRLD) Surveillance Report
M. Greskevitch (2003)
diffuse malignant mesothelioma. Thorax
C Gilks B. Hegedus (1988)
National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
L. Travis (2005)
Interim State Population Projections
U. S. Census Bureau (2005)
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors
J. Richie (2006)
US mesothelioma patterns 1973–2002: indicators of change and insights into background rates
M. J. Teta (2008)
Trends in mesothelioma incidence in the United States and the forecast epidemic due to asbestos exposure during World War II
J Peto (1981)
Malignant Mesothelioma of the Peritoneum Presenting as an Inflammatory Lesion: A Report of Four Cases
S. Kerrigan (2003)
Ships for Victory: A History of Shipbuilding under the U.S. Maritime Commission in World War II
F. Lane (1953)
Bethesda, MD: National Cancer Institute, Division of Cancer Control & Population Sciences, Surveillance Research Program
SEER registries discussion. (2008)
Surveillance, Epidemiology, and End Results Program (www. seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9
Radiation associated with malignant pleural mesothelioma . Thorax
C. McDonaldJ (1991)
Radiation associated with malignant pleural mesothelioma . Thorax
C. McDonaldJ (1991)
State Cancer Registry of Connecticut
Malignant peritoneal mesothelioma after remote abdominal radiation
B. Gilks (1988)
Non‐asbestos‐related malignant mesothelioma. A review
J. T. Peterson (1984)
Changing trends in US mesothelioma incidence
H. Weill (2004)
Malignant mesothelioma secondary to chronic
G 612019–2021. Hillerdal (1985)
J. Espinosa Arranz (1994)
Health implications of environmental exposure to asbestos.
J. C. Mcdonald (1985)
Bethesda, MD: National Cancer Institute, Division of Cancer Control & Population Sciences
Radiation associated with
MD Baltimore (1991)
Estimating Lifetime and Age-Conditional Probabilities of Developing Cancer
L. Wun (1998)
Background incidence of mesothelioma: animal and human evidence.
E. B. Ilgren (1991)
Malignant mesothelioma: attributable risk of asbestos exposure.
R. Spirtas (1994)
Diffuse malignant epithelial
S Kerrigan (2002)
Therapeutic radiation for lymphoma
M. J. Teta (2007)
Radiation associated malignant pleural mesothelioma.
Y. Lerman (1991)
Role of asbestos and other fibres in the development of diffuse malignant mesothelioma.
A. Gibbs (1990)
U S Total (1969)
Malignant mesothelioma secondary to chronic inflammation and old scars. Two new cases and review of the literature
G. Hillerdal (1985)
The risk of secondary malignancies over 30 years after the treatment of non‐hodgkin lymphoma
L. Brown (2006)
This paper is referenced by
Comments to the SAB on the EPA document EPA/635/R-002A, “Draft Toxicological Review of Libby Amphibole Asbestos”
S. Moolgavkar (2012)
Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma.
K. Turner (2012)
Malignant Peritoneal Mesothelioma Without Asbestos Exposure
Hafsa Abbas (2019)
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
Laura M Enomoto (2019)
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
Patient-Derived Organotypic Tumor Spheroids Facilitate Precision Medicine Advances in Therapeutic Screening for Malignant Pleural Mesothelioma
Dalia Larios Chavez (2019)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
UK asbestos imports and mortality due to idiopathic pulmonary fibrosis.
C. Barber (2016)
Evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature
E. Donovan (2012)
Inference and forecasting in the age-period-cohort model with unknown exposure with an application to mesothelioma mortality
M. D. M. Miranda (2013)
Malignant Mesothelioma: Mechanism of Carcinogenesis
A. Kane (2014)
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
S. Jane Henley (2013)
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
M. Milano (2010)
Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
M. Comar (2014)
[Epidemiological and occupational medicine aspects of pleural mesothelioma].
B. Karabin-Kehl (2013)
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
Nadine L de Boer (2019)
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort
W. Amin (2018)
Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database
L. Bijelić (2020)
Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
Malik Hamaidia (2019)
Benign asbestos-related pleural disease.
Christopher King (2011)
Mesothelioma: an Orphan Disease?
Laurent Greillier (2016)
Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma
L. Chirieac (2019)
Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries.
H. Gibb (2013)
Intensity Modulated Radiation Therapy versus Supportive Care in Malignant Pleural Mesothelioma: A Pilot Study for Treatment Outcomes and Cost-Effective Expectations
M. Ellithy (2018)
Disparities in Compliance with National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
Fernando Espinoza-Mercado (2019)
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
Cancer Rehabilitation: A Concise and Portable Pocket Guide
Jennifer Baima (2020)
Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy
Yeon-Hee Park (2015)
Comparison of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Mitomycin or Carboplatin for Diffuse Malignant Peritoneal Mesothelioma
Shreya Shetty (2014)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)See more